Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Stopped early · Phase 1

Conditions studied: Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

In brief

This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib. The first part (Dose Escalation) will employ a standard 3+3 dose escalation design to determine Maximum Tolerated Dose (MTD). The second part of the study (Dose Confirmation) will confirm the recommended Phase 2 dose (RP2D) in an expanded population.

Key facts

Study ID: NCT03373877
Run by: Samus Therapeutics, Inc.
People needed: 4
Starts: 2018-05-24
Expected to finish: 2020-03-10
Last updated by the study team: 2022-11-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject has a confirmed diagnosis of myelofibrosis, including PMF, post-PV MF, and post-ET MF.
Subject has been receiving ruxolitinib therapy for intermediate or high-risk myelofibrosis for >6 months prior to enrollment with no more than 1 dose reduction of ruxolitinib in the 2-8 weeks prior to enrollment and a stable daily dose ≥5 mg twice daily (BID) >2 months prior to enrollment.
Subject has MF with evidence of persistent disease despite ruxolitinib monotherapy treatment, consisting of:
Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a MPN-SAF TSS score of >20 points; AND
Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam.
Subject has an Eastern Cooperative Oncology Group performance status of 0-2.
Acceptable pre-study organ function during screening defined as:
Absolute neutrophil count (ANC) ≥ 1000/uL
Hemoglobin (hgb) ≥ 8.0 g/dL (may be supported with transfusion)
Platelets (plt) ≥ 75,000/uL
AST/SGOT and ALT/SGPT ≤2 x Upper Limit of Normal (ULN)
Direct serum bilirubin ≤ 1.5 x ULN
Creatinine clearance >50 mL/min/1.73 m2 based on Cockcroft Gault equation.

You may not qualify if…

Subject has known active liver disease, including viral hepatitis or cirrhosis.
Subject has known or suspected HIV or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable.
Subject has a QTcF > 480 ms (corrected) in the screening or baseline ECG.
Subject has left ventricular ejection fraction (LVEF) ≤ 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
Subject has a history (or family history) of long QT syndrome.
Subject has coronary artery disease with an ischemic event within 6 months prior to enrollment.
Subject has a permanent cardiac pacemaker.
Subject has history of a second primary malignancy within the past 2 year except for the following (if appropriately treated and considered cured): stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer.
Subject has significant uncontrolled medical condition within 6 months prior to enrollment, as determined by the investigator.
Subject has concurrent participation in any interventional studies within 14 days of first dose of study drug.
Subject has uncontrolled diabetes mellitus, in the judgment of the Principal Investigator.
Subject has an active ocular condition that in the opinion of the investigator may alter visual acuity during the course of the study (i.e., ocular inflammatory disease etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study.

Where it is running

Yale Cancer Center — New Haven, Connecticut, United States
Ochsner Clinic Foundation — New Orleans, Louisiana, United States
University of Michigan — Ann Arbor, Michigan, United States
Karmanos Cancer Institute — Detroit, Michigan, United States
University of Nebraska Medical Center — Omaha, Nebraska, United States
Duke University Medical Center — Durham, North Carolina, United States
Cleveland Clinic - Taussig Cancer Institute — Cleveland, Ohio, United States
Abramson Cancer Center - University of Pennsylvania — Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center — Houston, Texas, United States
Mays Cancer Center UT Health San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.